il 9

Anti-IL-9 Antibody (MH9A4)，一种小鼠IgG2b, κ 嵌合抗体，针对IL-9(人源)进行特异性靶向。该抗体的同型对照产品为 MouseIgG2bkappa, Isotype Control。

Anti-MouseIL-9Antibody (9C1) 是一种来源于小鼠的IgG2a抗体，用于抑制小鼠IL-9。

IL-17 modulator9 (compound 453) 为一种具有口服活性的IL-17调节剂，能显著减少IL-6、IFN-γ及水肿的表现，常用于炎症研究领域。

Anti-MouseIL-21RAntibody (4A9) 是一种大鼠来源的IgG2a, κ抗体抑制剂，用于阻止小鼠IL-21R的活性。

Anti-mouse IL-1a(9H10)抗体，靶向 IL-1a。

Anti-IL-4R Antibody (9C602) 是一种靶向人 IL-4R 的单克隆抗体，是一种 Rabbit IgG 抗体。

Anti-IL-17 Antibody (9A950) 是一种靶向人 IL-17 的单克隆抗体，是一种 Mouse IgG1 抗体。

Cyclo-olivil-9-O-β-glucopyranoside 可以从 Urtica triangularis HAND-MASS 的根部提取。该化合物适用于药物开发领域。

Muscone (3-Methylcyclopentadecanone) 是中药麝香的一种主要活性单体。它抑制NF-κB 和NLRP3炎性小体的活化，显著降低炎性细胞因子水平，并最终改善心脏功能和存活率。

Berberrubine chloride (9-Berberoline Chloride) 是一种黄连素的有效代谢物，能够改善动物模型中溃疡性结肠炎的症状。

CU-T12-9 是特异性 TLR1 2激动剂，可激活先天免疫系统和适应性免疫系统。它选择性激活 TLR1 2 异二聚体，可通过促进 TLR1 和 TLR2 二聚而激活 NF-κB 信号，引起下游 TNF-α、IL-10 和 iNOS 增加。

M199, a novel inhibitor of TLR3 9 activation, induces secretion of IL-6, IL-8 and TNFalpha in human PBMCs.

Glucocorticoid receptor modulator1 是一种高效且具有口服活性的 NF-κB 和 AP-1抑制剂，IC50分别为 9 nM 和 130 nM。Glucocorticoid receptor modulator1 可有效降低炎症因子 IL-6、IL-1β、TNF-α 的表达，可缓解小鼠皮炎。

CB2 receptor agonist 9 (Compound 33) 是一种有效的口服大麻素受体 2 (CB2 receptor) 激动剂，EC50 为 16.2 nM。CB2 receptor agonist 9 能抑制 TNF-α、IL-1β 和 IL-6 的表达，并在 DDS 诱导的小鼠急性结肠炎模型中显示抗炎活性。

PDE1-IN-9 (Compound 7a) 为磷酸二酯酶 1 (PDE1) 的选择性抑制剂，其可抑制PDE1C，IC50为11 nM。PDE1-IN-9 能降低IL-1β、IL-6、TNF-α 和 iNOS的mRNA表达，并抑制一氧化氮 (NO) 和活性氧 (ROS) 的产生。此外，该化合物在大鼠肝微粒体中显示出良好的代谢稳定性。

Cobitolimod sodium 是 TLR-9 的 DNA 寡核酸激动剂，具有抗炎活性。它可抑制 Th17 细胞并诱导抗炎 FoxP3 和 IL-10 表达，同时抑制 IL-17 信号通路。

(+)-9'-O-trans-feruloyl-5,5'-dimethoxylariciresinol may have anti-allergic inflammatory effect, it can inhibit release of histamine from mast cells. It shows cytotoxicity against a small panel of human tumor cell lines, with ED50 values of 9.86 to approxi

Skullcapflavone I has anti-inflammatory and anti-allergic potential, it can significantly inhibit LPS stimulated NO and PGE(2) release in J774A.1 macrophages and inhibit LPS induced IL-6 production in a concentration dependent manner. Skullcapflavone I se

Cobitolimod, a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory properties, suppresses Th17 cells and promotes the expression of anti-inflammatory FoxP3 and IL-10, thereby inhibiting the IL-17 signaling pathway [1].

ITH15004 is a non-nucleotide antagonist of the purinergic P2X7receptor (IC50= 9 μM in HEK293 cells expressing the human receptor).1It inhibits ATP-induced currents inX. laevisoocytes expressing the human P2X7receptor when used at a concentration of 100 μM. ITH15004 (1 μM) decreases IL-1β release from LPS-primed, ATP-stimulated isolated mouse peritoneal macrophages. It has high permeability in a parallel artificial membrane permeability assay (PAMPA). 1.Calzaferri, F., Narros-Fernández, P., de Pascual, R., et al.Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammationJ. Med. Chem.64(4)2272-2290(2021)

β-Defensin-2 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts.1It inhibits the growth of periodontopathogenic and cariogenic bacteria, includingP. gingivalisandS. salivarius.2β-Defensin-2 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes.3It also stimulates calcium mobilization, migration, and proliferation of keratinocytes when used at concentrations of 30, 10, and 40 μg/ml, respectively. β-Defensin-2 induces IL-31 production by human peripheral blood-derived mast cellsin vitrowhen used at a concentration of 10 μg/ml and by rat mast cellsin vivofollowing a 500 ng intradermal dose.4Expression of β-defensin-2 is increased in psoriatic skin and chronic wounds.5,6 1.Lehrer, R.I.Primate defensinsNat. Rev. Microbiol.2(9)727-738(2004) 2.Ouhara, K., Komatsuzawa, H., Yamada, S., et al.Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cellsJ. Antimicrob. Chemother.55(6)888-896(2005) 3.Niyonsaba, F., Ushio, H., Nakano, N., et al.Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokinesJ. Invest. Dermatol.127(3)594-604(2007) 4.Niyonsaba, F., Ushio, H., Hara, M., et al.Antimicrobial peptides human β-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cellsJ. Immunol.184(7)3526-3534(2010) 5.Huh, W.-K., Oono, T., Shirafuji, Y., et al.Dynamic alteration of human β-defensin 2 localization from cytoplasm to intercellular space in psoriatic skinJ. Mol. Med. (Berl.)80(10)678-684(2002) 6.Butmarc, J., Yufit, T., Carson, P., et al.Human β-defensin-2 expression is increased in chronic woundsWound Repair Regen.12(4)439-443(2004)

Glaucine 是从海罂粟中分离的一种生物碱，具有镇咳、抗炎和支气管扩张作用。它是具有口服活性的磷酸二酯酶 4 选择性抑制剂。它还是非选择性的 α-肾上腺素受体拮抗剂，具有抗氧化和抗病毒活性。

Mogroside IIe 是一种天然来源的三萜糖苷，作为非糖类甜味剂，Mogroside 比蔗糖更甜。Mogroside 具有抗氧化，抗糖尿病和抗癌活性。

Lornoxicam-d4 is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells, which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells, which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg kg. Formulations containing lornoxicam have been used in the management of postoperative pain.